| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16:46 | Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline | ||
| 12:46 | Vertex signs agreement to acquire Crinetics for $10bn | ||
| 11:46 | EC approves AbbVie's Tepkinly combination for follicular lymphoma | ||
| Mo | UK biotechs struggling to access finance as scale-up concerns grow | ||
| Mo | Novartis to acquire Myricx Bio in up to $1.5bn deal | ||
| Mo | Roche pens $490m Astex breast cancer license deal | ||
| Mo | Besins Healthcare boosts drug delivery portfolio with UniD deal | ||
| Fr | WHO intensifies Ebola-curbing efforts through drug trial and diagnostic rollout | ||
| Fr | US-UK pharma trade deal paints a costly economic picture for NHS | ||
| Fr | SK bioscience to lead Gates Foundation-funded ROTOR project | ||
| Fr | European Commission approves Novartis' Itvisma to treat SMA | ||
| Do | Ipsen bolsters rare disease pipeline in €700m Memo takeover | ||
| Do | FDA widens Vertex's Casgevy use for paediatric patients | ||
| Do | Insilico Medicine, Takeda partner on AI-driven drug discovery | ||
| Do | Inocras, AimedBio team up for cancer treatments | ||
| Mi | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | ||
| Mi | Sanofi aims for Nexviazyme approval in younger Pompe disease patients | ||
| Mi | Anthropic debuts AI-driven pharma R&D tool, Claude Science | ||
| Mi | Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown | ||
| Mi | US FDA rejects approval of Unicycive's kidney disease therapy | ||
| Mi | Eli Lilly and Innovent agree Verzenios commercialisation deal in China | ||
| 30.06. | Lilly and Regeneron amongst first incumbents to FDA's fast-track facility scheme | ||
| 30.06. | Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger | ||
| 30.06. | Anixa Biosciences secures Korean patent for breast cancer vaccine | ||
| 30.06. | Zymeworks agrees to buy Theravance Biopharma for $929m |